HYEX · Healthy Extracts Inc.
$1.17
-0.07 (-5.61%)
At close · Aug 25
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to its neutral cash flow, the Company has doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued. In addition, most of the Company's development activities since inception have been financially sustained through equity financing but it is using all additional cash flow to help support the Company's growth and research and development of new products. Management plans to keep seeking funding through debt and equity financing which are intended to mitigate the conditions that have raise substantial doubt about the entity's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$17.25M
Shares
14.74M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.17
Open$1.17
Day$1.17–1.17
52W close$0.84–3.35
Avg vol 30d724
Short int93 · 0.0% float · 1.0d
Short vol100%
DataJan 2024–Aug 2026
Filing10-Q · Aug 14
Raw chart and full-history price indicators begin at the captured split on Dec 29, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$6.29M
Trailing 12 months
Net income (TTM)
−$879,358
Trailing 12 months
Revenue growth YoY
+113.4%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$189,958
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+47.9%
Year over year · more shares
Price change (1Y)
-64.8%
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
−22%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
13%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−33%
trailing
6-month return
−30%
trailing
YTD return
−23%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -92.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Revenue growth
+45%
Y/Y
Gross margin
54%
contracting
Free cash flow
$165.5K
Quant / Vol
risk profile
Volatility
273%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
16.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
13%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -92.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $1
Now $1 · 13%
Range high $3
vs 200-day avg -43%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HYEX
this stock
Healthy Extracts Inc.
|
$17.25M | -23.0% | +44.9% | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.66B | +16.9% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$47.69B | -1.4% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.35B | -0.4% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
Raw-price comparisons begin at the captured split on Dec 29, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HYEX | -22.0% | -33.1% | -29.5% | -2.0% | -23.0% |
| SPY | -0.2% | +3.4% | +11.8% | +2.5% | +12.3% |
| vs SPY | -21.8% | -36.5% | -41.3% | -4.5% | -35.4% |